Understanding how CD19 expression levels impact the response to loncastuximab tesirine
This Plain Language Summary of publication article (PLSP) from Future Oncology, summarizes findings from the LOTIS-2 study, which evaluated loncastuximab tesirine (Lonca) in patients with diffuse large B-cell lymphoma (DLBCL). Researchers used patient data from LOTIS-2, other Lonca studies, and scientific publications to create a quantitative systems pharmacology (QSP) model. The model examined whether CD19 levels on tumor cells could predict tumor size changes after Lonca treatment and assessed Lonca’s effectiveness in cases with very low CD19 levels.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine’ and was published in eJHaem
Visit Wiley using the link to read the original article.